Registry Experience at the Washington Hospital Center, DES - Xience V

Interventional cardiology was revolutionized by the invention of stents, initially with the bare-metal stents (BMS) and recently with the drug-eluting stents (DES). The everolimus eluting, Xience V stents have shown very promising results in randomized clinical trials, demonstrating a reduction of clinical and angiographic restenosis in comparison to BMS, and comparable clinically-driven target lesion revascularization rates in comparison with sirolimus-eluting stents. While registry data is available from outside of the United States, it will be important to collect "real-world" data regarding the stent usage and outcomes in the United States. In this study we propose to follow patients who received at least one Xience V® Stent for at least 1 year post initial stent implantation.

Inclusion criteria

• Patients, male or female, >18 years of age
• Patients who received at least one Xience V drug-eluting stent at the Washington Hospital Center

Exclusion criteria

• Patients who received another type of DES (other than Xience V) or a bare metal stent at the time of initial Xience V stent implantation